In light of the strong inhibition of Runx2 expression, however, BRD inhibitors might not be ideally suited for osteoporosis treatment, since the transcription factor Runx2 is needed for the onset of osteoblast differentiation from MSCs [109]. This evidence concerns the gene RUNX2 and osteoporosis.